PURPOSE: Anxiety is common in patients undergoing radiation therapy (RT) and in their family caregivers (FCs). Little is known about individual differences in anxiety trajectories during and after RT. This study aimed to identify distinct latent classes of oncology patients and their FCs based on self-reported anxiety symptoms from the beginning to four months after the completion of RT. METHOD: Using growth mixture modeling (GMM), longitudinal changes in Spielberger State Anxiety Inventory (STAI-S) scores among 167 oncology outpatients with breast, prostate, lung, or brain cancer and 85 FCs were evaluated to determine distinct anxiety symptom profiles. STAI-S scores were assessed just prior to, throughout the course of, and for four months following RT (total of 7 assessments). Baseline trait anxiety and depressive symptoms (during and after RT) were also assessed. RESULTS: The GMM analysis identified three latent classes of oncology patients and FCs with distinct trajectories of state anxiety: Low Stable (n = 93, 36.9%), Intermediate Decelerating (n = 82, 32.5%), and High (n = 77, 30.6%) classes. Younger participants, women, ethnic minorities, and those with children at home were more likely to be classified in the High anxiety class. Higher levels of trait anxiety and depressive symptoms, at the initiation of RT, were associated with being in the High anxiety class. CONCLUSIONS: Subgroups of patients and FCs with high, intermediate, and low mean levels of anxiety during and after RT were identified with GMM. Additional research is needed to better understand the heterogeneity of symptom experiences as well as comorbid symptoms in patients and FCs.
PURPOSE:Anxiety is common in patients undergoing radiation therapy (RT) and in their family caregivers (FCs). Little is known about individual differences in anxiety trajectories during and after RT. This study aimed to identify distinct latent classes of oncology patients and their FCs based on self-reported anxiety symptoms from the beginning to four months after the completion of RT. METHOD: Using growth mixture modeling (GMM), longitudinal changes in Spielberger State Anxiety Inventory (STAI-S) scores among 167 oncology outpatients with breast, prostate, lung, or brain cancer and 85 FCs were evaluated to determine distinct anxiety symptom profiles. STAI-S scores were assessed just prior to, throughout the course of, and for four months following RT (total of 7 assessments). Baseline trait anxiety and depressive symptoms (during and after RT) were also assessed. RESULTS: The GMM analysis identified three latent classes of oncology patients and FCs with distinct trajectories of state anxiety: Low Stable (n = 93, 36.9%), Intermediate Decelerating (n = 82, 32.5%), and High (n = 77, 30.6%) classes. Younger participants, women, ethnic minorities, and those with children at home were more likely to be classified in the High anxiety class. Higher levels of trait anxiety and depressive symptoms, at the initiation of RT, were associated with being in the High anxiety class. CONCLUSIONS: Subgroups of patients and FCs with high, intermediate, and low mean levels of anxiety during and after RT were identified with GMM. Additional research is needed to better understand the heterogeneity of symptom experiences as well as comorbid symptoms in patients and FCs.
Authors: Inge Henselmans; Vicki S Helgeson; Howard Seltman; Jakob de Vries; Robbert Sanderman; Adelita V Ranchor Journal: Health Psychol Date: 2010-03 Impact factor: 4.267
Authors: Wendy W T Lam; George A Bonanno; Anthony D Mancini; Samuel Ho; Miranda Chan; Wai Ka Hung; Amy Or; Richard Fielding Journal: Psychooncology Date: 2010-10 Impact factor: 3.894
Authors: Bradley E Aouizerat; Marylin Dodd; Kathryn Lee; Claudia West; Steven M Paul; Bruce A Cooper; William Wara; Patrick Swift; Laura B Dunn; Christine Miaskowski Journal: Biol Res Nurs Date: 2009-05-05 Impact factor: 2.522
Authors: Kimberly E Alexander; Bruce A Cooper; Steven M Paul; Patsy Yates; Bradley E Aouizerat; Christine Miaskowski Journal: Qual Life Res Date: 2016-05-09 Impact factor: 4.147
Authors: Anand Dhruva; Bradley E Aouizerat; Bruce Cooper; Steven M Paul; Marylin Dodd; Claudia West; William Wara; Kathryn Lee; Laura B Dunn; Dale J Langford; John D Merriman; Christina Baggott; Janine Cataldo; Christine Ritchie; Kord Kober; Heather Leutwyler; Christine Miaskowski Journal: Eur J Oncol Nurs Date: 2013-09-05 Impact factor: 2.398
Authors: Dale J Langford; Claudia West; Charles Elboim; Bruce A Cooper; Gary Abrams; Steven M Paul; Brian L Schmidt; Jon D Levine; John D Merriman; Anand Dhruva; John Neuhaus; Heather Leutwyler; Christina Baggott; Carmen Ward Sullivan; Bradley E Aouizerat; Christine Miaskowski Journal: J Neurogenet Date: 2014-01-07 Impact factor: 1.250
Authors: Yobelli A Jimenez; Steven Cumming; Wei Wang; Kirsty Stuart; David I Thwaites; Sarah J Lewis Journal: Support Care Cancer Date: 2018-03-13 Impact factor: 3.603
Authors: John D Merriman; Bradley E Aouizerat; Janine K Cataldo; Laura Dunn; Bruce A Cooper; Claudia West; Steven M Paul; Christina R Baggott; Anand Dhruva; Kord Kober; Dale J Langford; Heather Leutwyler; Christine S Ritchie; Gary Abrams; Marylin Dodd; Charles Elboim; Deborah Hamolsky; Michelle Melisko; Christine Miaskowski Journal: Cytokine Date: 2013-12-04 Impact factor: 3.861
Authors: John D Merriman; Bradley E Aouizerat; Dale J Langford; Bruce A Cooper; Christina R Baggott; Janine K Cataldo; Anand Dhruva; Laura Dunn; Claudia West; Steven M Paul; Christine S Ritchie; Patrick S Swift; Christine Miaskowski Journal: Biol Res Nurs Date: 2013-03-11 Impact factor: 2.522